KPF
JSPR icon

K2 Principal Fund’s Jasper Therapeutics JSPR Stock Holding History

K2 Principal Fund’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,746
Closed -$2.46M – 339
2021
Q2 		$2.46M Buy
24,746
+20,000
+421% +$1.99M 0.2% 143
2021
Q1 		$470K Buy
+4,746
New +$483K 0.04% 254

Other funds holding JSPR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

K2 Principal Fund's JSPR Position: Q3 2021 in Review

K2 Principal Fund sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 24,746 shares — an estimated $2.46M sold.

K2 Principal Fund first reported a position in JSPR in Q1 2021 and held it in 2 quarters. The position peaked at $2.46M in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • K2 Principal Fund reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • K2 Principal Fund sold 24,746 Jasper Therapeutics shares in Q3 2021, an estimated $2.46M.
  • K2 Principal Fund first reported a position in Jasper Therapeutics in Q1 2021 and held it in 2 quarters.
  • K2 Principal Fund's Jasper Therapeutics position peaked at $2.46M in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on K2 Principal Fund's 13F filing for Q3 2021, filed 12 Nov 2021.